ADT

PointClickCare and C3HIE Collaborate to Enable Smoother and Safer Care Transitions for Patients Across the State of Texas

Retrieved on: 
水曜日, 5月 29, 2024
Technology, Hospitals, Health Technology, Professional Services, Software, Practice Management, Managed Care, Data Analytics, Health, Data Management, Partnership, Patient, Learning, Hospital, Organization, EDEN, SNF, Senior, ADT, Emergency department, Acos, History, Nursing

PointClickCare , a leading healthcare technology platform enabling meaningful care collaboration and real-time patient insights, and C3HIE , a community partner offering additional critical interoperability and care coordination services, announced today its first direct partnership.

Key Points: 
  • PointClickCare , a leading healthcare technology platform enabling meaningful care collaboration and real-time patient insights, and C3HIE , a community partner offering additional critical interoperability and care coordination services, announced today its first direct partnership.
  • Together, the organizations are working towards a goal of improving health outcomes patients across the state of Texas and ensuring a more connected care experience at every stage of the patient healthcare journey.
  • This collaboration will further enable smoother and safer care transitions by bringing C3HIE’s admission, discharge, and transfer (ADT) data to PointClickCare’s comprehensive platform, while adding PointClickCare's expansive Skilled Nursing Facility (SNF) data into the C3HIE network.
  • This partnership aligns with C3HIE's mission of making the healthcare community more connected and collaborative," says Phil Beckett , CEO, C3HIE.

Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18), Axumin® (Fluciclovine F 18) and Investigational 18F-Flotufolastat/18F-rhPSMA-7 at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Retrieved on: 
水曜日, 5月 29, 2024
Oncology, Health, Clinical Trials, General Health, Radiology, Biotechnology, PET, Blood pressure, Diarrhea, Doctor of Philosophy, Recurrence, Exhibit, Risk, University, SNMMI, FDA, Lymph, Serum, Radiation, Level, MD, ADT, Prostate cancer, PSA, Cancer, Dysgeusia, MedStar Georgetown University Hospital, F 18, Anaphylaxis, Antiandrogen, Medical imaging

Blue Earth Diagnostics invites participants at the 2024 SNMMI Annual Meeting to attend the presentations above and to visit the Company at Exhibit Booth 1639.

Key Points: 
  • Blue Earth Diagnostics invites participants at the 2024 SNMMI Annual Meeting to attend the presentations above and to visit the Company at Exhibit Booth 1639.
  • The Company is hosting a Satellite Symposium, “Let’s Talk about POSLUMA®,” which will discuss the most recent innovations in PSMA-PET imaging for prostate cancer.
  • Blue Earth Diagnostics also has a Medical Affairs information booth at SNMMI, where attendees can learn about the Company’s clinical research.
  • A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence.

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

Retrieved on: 
木曜日, 5月 16, 2024
Patient, Cohort (statistics), Doctor of Philosophy, University, Weight gain, Genetic testing, Myriad Genetics, Risk, JCO, MYGN, Male, Huntsman Cancer Institute, Conference, CCR, MD, ADT, Death, Prostate cancer, Genetics, ASCO, Medicine, Poster, Society, RT, Metastasis

SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen deprivation therapy (ADT) to radiation therapy (RT) in men with localized prostate cancer.

Key Points: 
  • (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen deprivation therapy (ADT) to radiation therapy (RT) in men with localized prostate cancer.
  • Guidelines currently recommend adding ADT to RT in certain patients with localized prostate cancer.
  • However, patients with a Prolaris CCR score above the multimodal threshold can reduce risk of metastasis by 8.19% on average by adding ADT to RT.
  • In consultation with their providers, many of these men may elect to forgo ADT based on the information in their Prolaris reports.”

Bayer presents latest data from oncology portfolio at 2024 ASCO Annual Meeting

Retrieved on: 
木曜日, 5月 16, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Darolutamide, Patient, Survival, Disease, Phase, NTRK, Risk, TRK, HER2, Docetaxel, Prostate cancer, Prostate-specific antigen, Safety, NSCLC, BCR, ADT, PSA, Metastasis, ASCO, Abstract, Society, Mutation, Annual general meeting, Pharmaceutical industry

Bayer will present new data across its oncology portfolio at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, from May 31 – June 4, 2024.

Key Points: 
  • Bayer will present new data across its oncology portfolio at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, from May 31 – June 4, 2024.
  • The breadth of new data in different tumor types underscores Bayer’s ambition to deliver innovative and effective oncological therapies in areas with the highest unmet medical needs.
  • Prostate cancer is a key focus for Bayer Oncology, with data to be presented on NUBEQA® (darolutamide) and XOFIGO® (radium Ra 223 dichloride) across multiple stages of the disease.
  • An overview of the ongoing investigational Phase III ARASTEP trial in hormone sensitive prostate cancer patients with high-risk biochemical recurrence will also be presented.

WEST MINING CORP. ANNOUNCES RICHARD LONSDALE-HANDS TO THE ADVISORY BOARD

Retrieved on: 
水曜日, 5月 8, 2024
Investment, OTC, Robeco, Insurance, ADT, Conference, ADC, BMA, AMP, AASF, FIPP, ADIA, FRA

VANCOUVER, B.C., May 08, 2024 (GLOBE NEWSWIRE) -- WEST MINING CORP. (“WEST” OR THE “COMPANY”) (CSE: WEST) (OTC: WESMF) (FRA: 1HL) is pleased to announce the appointment of Richard Lonsdale-Hands to its advisory board.

Key Points: 
  • VANCOUVER, B.C., May 08, 2024 (GLOBE NEWSWIRE) -- WEST MINING CORP. (“WEST” OR THE “COMPANY”) (CSE: WEST) (OTC: WESMF) (FRA: 1HL) is pleased to announce the appointment of Richard Lonsdale-Hands to its advisory board.
  • Mr. Lonsdale-Hands is a seasoned investor with over 50 years of experience in investment banking, resources and property management.
  • He has held many significant roles of director, president, managing director and advisor with multiple small and large capitalization companies throughout his career.
  • Nader Vatanchi, West Mining’s Chief Executive Officer, said “we welcome Mr. Lonsdale-Hands and his years of experience to the Company.

West Mining Corp. Announces Richard Lonsdale-Hands to the Advisory Board

Retrieved on: 
水曜日, 5月 8, 2024
Investment, OTC, Robeco, Insurance, ADT, Conference, ADC, BMA, AMP, AASF, FIPP, ADIA, FRA

VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- WEST MINING CORP. (“WEST” OR THE “COMPANY”) (CSE: WEST) (OTC: WESMF) (FRA: 1HL) is pleased to announce the appointment of Richard Lonsdale-Hands to its advisory board.

Key Points: 
  • VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- WEST MINING CORP. (“WEST” OR THE “COMPANY”) (CSE: WEST) (OTC: WESMF) (FRA: 1HL) is pleased to announce the appointment of Richard Lonsdale-Hands to its advisory board.
  • Mr. Lonsdale-Hands is a seasoned investor with over 50 years of experience in investment banking, resources and property management.
  • He has held many significant roles of director, president, managing director and advisor with multiple small and large capitalization companies throughout his career.
  • Nader Vatanchi, West Mining’s Chief Executive Officer, said, “We welcome Mr. Lonsdale-Hands and his years of experience to the Company.

ConsumerAffairs recognizes 12 companies for home safety, pest control, flooring and hearing aids in 2024 Buyer's Choice Awards

Retrieved on: 
水曜日, 5月 8, 2024
Bulwark, AI, OTC, ADT, Vivint, LL Flooring, Procurement, Orkin, Pest control, Vector Security, ConsumerAffairs, Carman, Web Cartoonists' Choice Awards, Auction

Orkin Pest Control took home each of the pest control awards: Best Customer Service, Best Experience with Staff, Best Speed of Service and Best Value for Price.

Key Points: 
  • Orkin Pest Control took home each of the pest control awards: Best Customer Service, Best Experience with Staff, Best Speed of Service and Best Value for Price.
  • Finally, hear.com and Starkey Hearing Aids won all of their category awards: Best Customer Service, Best Experience with Staff and Best Value for Price.
  • Pest Control: Bulwark Exterminating (three awards: Best Customer Service, Best Experience with Staff and Best Speed of Service) and Hawx Pest Control (one award: Best Value for Price).
  • Home alarm: ADT (three awards: Best Customer Service, Best Equipment and Best Monitoring) and Vector Security (three awards: Best Customer Service, Best for Installation and Best Monitoring)
    For more information about the Buyer's Choice Awards and the recognized companies, please visit the awards page .

Twenty-eighth Annual CONNECTIONS™ Conference Addresses Growth of Technology in Consumer and Business, Including Smart Home, Security, Health, and Entertainment

Retrieved on: 
火曜日, 5月 7, 2024
Trident, Alarm.com, Sale, Networking hardware, EPB, Internet, Early, Ecosystem, Amazon Web Services, Advertising, AI, Verizon Communications, Silicon Labs, ADT, Generali, Imperial Capital, RapidSOS, Luigi, Cardinal Peak, SmartThings, Control, AWS, Artificial intelligence, Wyze, Television

DALLAS, May 7, 2024 /PRNewswire/ -- Parks Associates will feature key findings from its research Smart Home: Integration, Automation, and Control at the 28th annual CONNECTIONS™: The Premier Connected Home Conference, May 7-9 at the Hilton Dallas/Plano Granite Park Hotel in Plano, TX. The executive conference addresses the consumer and small to medium buyer journey for technology solutions.

Key Points: 
  • The executive conference addresses the consumer and small to medium buyer journey for technology solutions.
  • The firm's research shows spur-of-the-moment and experiential shopping are the top triggers for smart home device purchases.
  • Consumers have gaps in their daily activities where technology can help provide convenience, context, and valuable information.
  • Smart video doorbells are the most popular device, with 32% of US internet households planning to buy one in the next six months, followed by smart cameras, smart smoke/CO detectors, and smart lights.

Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery

Retrieved on: 
金曜日, 5月 3, 2024
BCR, RP, Risk, Johnson & Johnson, Recurrence, ADT, Research, Abstract, Prostate cancer, Disease, Patient, Urology, Neoplasm, Surgical oncology, SAN, Pharmaceutical industry

SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP). Following RP, patients who received the treatment regimen showed a 100% biochemical recurrence (BCR)–free rate at 24 months.1 These data were presented today at an Oral Presentation Session (Abstract #P2-07) at the 2024 American Urological Association Annual Meeting AUA, May 3-6, 2024, in San Antonio, Texas. 

Key Points: 
  • SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP).
  • * "Results from this study encourage additional research for high-risk localized prostate cancer and highlight the promise of bringing treatment into earlier stages of disease following radical prostatectomy."
  • The study met its primary endpoint, showing that patients who received 12 months of ERLEADA® plus ADT adjuvant to RP experienced no confirmed biochemical recurrence after 12 additional months of follow-up.
  • The treatment regimen demonstrated a serum testosterone recovery (≥150 ng/dL) rate of 76.4% at 12 months (95% CI, 65.0–84.5).

HKEX Welcomes Asia's First Spot Virtual Asset ETFs

Retrieved on: 
火曜日, 4月 30, 2024
ETP, ETF, HKEX, Ecosystem, ADT, Spot

HONG KONG, April 30, 2024 /PRNewswire/ -- Hong Kong Exchanges and Clearing Limited (HKEX) is pleased to welcome the listing of Asia's first Spot Virtual Asset (VA) ETFs on 30 April (Hong Kong time), adding to the diversity of products in Hong Kong's markets and further supporting the city's position as the region's leading ETF marketplace by offering investors even more choice.

Key Points: 
  • HONG KONG, April 30, 2024 /PRNewswire/ -- Hong Kong Exchanges and Clearing Limited (HKEX) is pleased to welcome the listing of Asia's first Spot Virtual Asset (VA) ETFs on 30 April (Hong Kong time), adding to the diversity of products in Hong Kong's markets and further supporting the city's position as the region's leading ETF marketplace by offering investors even more choice.
  • HKEX Head of Equities Product Development, Brian Roberts, said: "The introduction of Spot VA ETFs in Hong Kong is the latest exciting addition to HKEX's diverse and vibrant ETP ecosystem, providing investors with access to a new asset class.
  • Following the success of VA Futures ETFs, the listing of Asia's first spot VA ETFs will further enhance the product diversity and liquidity of the Hong Kong ETP market.
  • Investor interest in virtual asset ETFs has grown since VA Futures ETFs were first launched in late 2022.